NCT03262558

Brief Summary

Cardiac surgery with extracorporeal circulation (ECC) yields a deep immune system dysfunction that exposes patients to postoperative infectious complications. Among these, post-operative mediastinitis with Staphylococcus aureus (SA) generates significant morbidity and mortality. Two radically different approaches have been proposed in recent years to reduce the incidence of this complication. A first approach has attempted, without real success, to decrease postoperative immunosuppression. The second, more efficient, consisted of screening and preoperatively treating patients colonized with SA. However, although its incidence has decreased, postoperative mediastinitis remains a terrible nosocomial infection. The authors believe that a thorough analysis of the immunological changes induced by cardiac surgery will initiate active therapeutics to reduce the post-operative immunosuppression phase, thereby decreasing the risk of nosocomial infections. In addition, a study of the interactions between the operated (host) and staphylococcus aureus (pathogenic) immune systems will provide a better understanding of the mechanisms that expose patients to this bacterium.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
27

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2016

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 4, 2016

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2017

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 22, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 25, 2017

Completed
2.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 29, 2019

Completed
Last Updated

December 14, 2022

Status Verified

December 1, 2022

Enrollment Period

12 months

First QC Date

August 22, 2017

Last Update Submit

December 13, 2022

Conditions

Keywords

staphylococcus aureusnosocomial infection

Outcome Measures

Primary Outcomes (1)

  • Variation of plasma IDO activity

    IDO activity is evaluated by the Kynurenin / Tryptophan ratio before and after ECC. Enzymatic activities will be measured by high performance liquid chromatography (HPLC) on pre- and post-operative blood tests

    Baseline and the morning following surgery

Secondary Outcomes (10)

  • Variation of phagocytosis capacity of PMNs

    Baseline and the morning following surgery

  • Variation of bactericidal capacity of PMNs

    Baseline and the morning following surgery

  • Variation of phagocytosis capacity of macrophages

    Baseline and the morning following surgery

  • Variation of bactericidal capacity of macrophages

    Baseline and the morning following surgery

  • Effect of an inhibitor of IDO on phagocytosis capacities of PMNs

    The day following surgery

  • +5 more secondary outcomes

Study Arms (1)

Patients with ECC

No intervention

Other: No intervention

Interventions

Patients will undergo standard clinical routine practice in this indication

Patients with ECC

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients in the aftermath of an ECC for cardiac surgery are investigated to look for the origin of a hypo-reactivity of PMNs and macrophages during exposure to staphylococcus aureus

You may qualify if:

  • Patients over 18 years of age
  • Patients who require cardiac surgery (valvular and / or coronary) with extracorporeal circulation.
  • Chronic respiratory diseases,
  • Preoperative left ventricular dysfunction (LVEF \<50%),
  • Immunosuppression (HIV infection, systemic corticosteroid therapy, history of cancer in the year before surgery),
  • Persons subject to legal protection (safeguard of justice, curatorship, guardianship),
  • Persons deprived of liberty.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rennes Hospital University

Rennes, 35033, France

Location

MeSH Terms

Conditions

InfectionsStaphylococcal InfectionsCross Infection

Condition Hierarchy (Ancestors)

Gram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesIatrogenic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jean-Marc TADIE, Md, PhD

    CHU Rennes

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 22, 2017

First Posted

August 25, 2017

Study Start

July 4, 2016

Primary Completion

July 1, 2017

Study Completion

September 29, 2019

Last Updated

December 14, 2022

Record last verified: 2022-12

Data Sharing

IPD Sharing
Will not share

Locations